IRadimed Corp, a leading provider of innovative magnetic resonance imaging (MRI) solutions, operates under a unique business model. The company specializes in the design, development, and manufacturing of groundbreaking MRI-compatible intravenous (IV) infusion pumps and related products. By focusing on this niche market, IRadimed Corp has established a strong competitive advantage. Their technologically advanced and FDA-approved products enable safe and precise delivery of fluids to patients during MRI procedures. Through strategic partnerships and a commitment to delivering high-quality healthcare solutions, IRadimed Corp continues to expand its presence in the global MRI market, enhancing patient care and revolutionizing the way IV infusion is administered in MRI settings.

IRadimed Corp is primarily active in the healthcare industry, specifically specializing in the development and manufacturing of innovative medical devices. The company focuses on creating advanced solutions for the delivery of intravenous medications and infusion therapy. With a strong presence in the medical technology sector, IRadimed Corp aims to improve patient care and enhance clinical outcomes through their cutting-edge products.

The main competitors of IRadimed Corp in the market are [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same industry as IRadimed Corp and offer similar products and services. However, IRadimed Corp stands out with its unique features, strong customer base, and innovative solutions. Despite facing competition, IRadimed Corp has managed to maintain a strong position in the market through its superior offerings and customer satisfaction.

IRadimed Corp, founded in 1992, is a leading provider of innovative magnetic resonance imaging (MRI) solutions. Headquartered in Winter Springs, Florida, the company specializes in the development and manufacturing of innovative MRI-compatible medical devices, including infusion pumps and vital signs monitoring systems. With a focus on patient safety and advanced technology, IRadimed Corp has established itself as a trusted name in the healthcare industry. The company's dedication to research and development has resulted in numerous patents and partnerships with top medical institutions. IRadimed Corp continues to expand its product portfolio and enhance healthcare outcomes through its cutting-edge solutions.

IRadimed Corp has achieved several significant milestones since its inception. The company has successfully introduced innovative medical device solutions, focusing on the development of MRI-compatible patient monitoring systems. With its cutting-edge technology, IRadimed Corp has revolutionized the healthcare industry by providing safe and accurate monitoring options for patients undergoing Magnetic Resonance Imaging (MRI) scans. The company's milestones include receiving FDA clearance for various products, expanding its global presence, securing strategic partnerships, and consistently offering high-quality, reliable products that enhance patient care during MRI procedures. IRadimed Corp's commitment to innovation and excellence has solidified its position as a leader in the MRI-compatible patient monitoring market.

IRadimed Corp is primarily present in the United States.

IRadimed Corp represents a commitment to innovation, excellence, and patient care. As a leading medical device company, their corporate philosophy centers around developing cutting-edge imaging solutions that enhance patient outcomes. IRadimed Corp values integrity, collaboration, and continuous improvement. Through their dedication to research and development, they strive to provide healthcare professionals with state-of-the-art products that improve diagnostic accuracy and patient safety. With a focus on customer satisfaction and clinical effectiveness, IRadimed Corp is dedicated to advancing the field of medical imaging and positively impacting the lives of patients worldwide.

Analysts currently set an average price target of 122.40 USD for the IRadimed stock (median: 122.40 USD), implying +34.7 % versus the latest price. The consensus is based on 8 analyst ratings.

IRadimed Analyst Price Targets 2026

8 analysts currently rate the IRadimed stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect IRadimed to generate revenue of 91.20 M USD and earnings per share of 2.07 USD.

IRadimed Analyst Price Targets 2026

Converted at the current exchange rate, the IRadimed share trades at 82.69 EUR (95.21 USD).

The IRadimed share (IRMD) is listed on 3 stock exchanges, including: NASDAQ (IRMD), Frankfurt (46K.F), Hamburg (46K.HM).

IRadimed Corp is a leading company and manufacturer of innovative medical devices and systems for use in healthcare. The company is known for its high-quality products and patented design, which allows for fast, secure, and efficient transmission of medical data. IRadimed Corp is divided into various business segments, which include a variety of products such as magnetic resonance imaging (MRI), intravenous contrast media injection, and invasive pressure monitoring. The MRI product line of IRadimed Corp is unique in the market and includes the MRidium system, specifically designed for use in magnetic resonance imaging rooms (MRI). The system is designed to meet the requirements of patient and image safety in the MRI room and allows for optimal and accurate patient monitoring. Other significant products of IRadimed Corp include the Flow-i anesthesia device and the InPatient satellite monitoring system. The Flow-i anesthesia device is a revolutionary development in anesthesiology and provides precise dosing of anesthetics and a quick response to patient needs. The InPatient satellite monitoring system allows medical personnel to monitor patients with real-time data from a central monitoring area. IRadimed Corp has a strong focus on research and development and continuously works to develop new products and technologies to meet the needs of healthcare. The company has a strong presence in the global market and is known for its high-quality products and excellent technical support and customer service. IRadimed Corp also has strong partnerships with companies like Siemens and Philips in the field of MRI technology and continuously works to improve both the technological capabilities and applicability of its products. Additionally, the company is actively involved in the community and participates in charity events and donation drives to make a positive contribution to society. Overall, IRadimed Corp is an innovative and advanced company focused on developing and providing cutting-edge products in healthcare. With a strong focus on technology and design and a commitment to excellent customer service, IRadimed Corp has achieved a leading position in the market and continues its successful corporate development.

The expected revenue of IRadimed is 91.20 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IRadimed is 26.67 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IRadimed is currently 45.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IRadimed stock.

The price-to-sales ratio (P/S) of IRadimed is currently 13.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IRadimed stock.

The Eulerpool Quality Score for IRadimed is 7/10.

The ISIN of IRadimed is US46266A1097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of IRadimed is A118V4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of IRadimed is IRMD. The ticker symbol is used to trade IRadimed shares on the stock exchange.

Over the past 12 months, IRadimed paid a dividend of 1.18 USD . This corresponds to a dividend yield of about 1.24 %. For the coming 12 months, IRadimed is expected to pay a dividend of 0.80 USD.

The current dividend yield of IRadimed is 1.24 %.

IRadimed pays a dividend, distributed in the months of , , , .

IRadimed paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 0.80 USD are expected. This corresponds to a dividend yield of 0.84 %.

IRadimed is assigned to the 'Health' sector.

To receive the latest dividend of IRadimed from amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, IRadimed distributed 0.45 USD as dividends.

The dividends of IRadimed are distributed in USD.